Health
GSK Scientists Close To Eradicating Gonorrhea Infection
Gonorrhea, a well-known Sexually Transmitted Infection (STI) often referred to as “The Gentleman’s Disease,” has a long-standing history and global prevalence.
However, scientists from GlaxoSmithKline (GSK) have expressed hope that the disease could soon be eradicated.
In recent years, the rise of drug-resistant strains of the bacteria responsible for gonorrhea, known as Neisseria gonorrhoeae, has significantly complicated its treatment with conventional medications.
As a result, the disease has become increasingly difficult to cure, nearing a state of near incurability.
The issue of antibiotic resistance in the treatment of gonorrhea has raised concerns due to the fact that all bacteria associated with the infection have developed resistance to at least one commonly used antibiotic.
Ceftriaxone, an intravenously administered medication, is currently in high demand but also faces increasing resistance.
While a legal vaccine for gonorrhea is not currently available, researchers have now set their sights on the potential of an injectable vaccine, which could offer a treatment option.
The investigational vaccine has successfully completed phase I studies, demonstrating its safety for human use, and is currently progressing through phase II trials.
The anticipated timeline suggests that final testing for the vaccine could commence as early as 2026, potentially opening up a new avenue for combating gonorrhea.
The US Food and Drug Administration (FDA) has taken proactive measures to expedite the development of an experimental vaccine aimed at eliminating the threat of gonorrhea.
This initiative is expected to accelerate the approval process and facilitate the swift dissemination of the vaccine among the general population.
In a comprehensive study, phase II trials involved 750 participants from eight countries, including the US, UK, France, and Spain. These individuals, aged between 18 and 50, were specifically selected due to their higher risk of contracting gonorrhea.
The phase II trials commenced in November 2022, and by March 2025, the results of this phase are anticipated to be available. Subsequently, phase III trials will commence, marking another significant step towards the potential availability of the vaccine.
Patients receive two doses of the vaccine by injection into the muscle in order to produce immunity. The vaccine’s mechanism of action is unknown, but researchers note that similar vaccines have been created in the past that employ antigens from bacterial surfaces to elicit an immune response.
The FDA’s decision to provide our novel vaccine candidate against Neisseria gonorrhoeae illness Fast Track designation is something we applaud, according to Phil Dormitzer, the global head of vaccine development at GSK.
The global prevalence of gonorrhea poses a significant threat to sexual and reproductive health worldwide. With its high and increasing incidence, the need for effective prevention measures is paramount.
The prospect of a vaccine holds great promise in potentially safeguarding millions of individuals from the severe health consequences associated with this infection caused by a bacterium categorized by the World Health Organization as a “high priority” pathogen.
Gonorrhea can easily spread from one person to another through vaginal contact with an infected partner. Additionally, there is a risk of perinatal transmission from mother to baby during childbirth.
However, it is worth noting that men face a considerable 20 percent chance of contracting the disease through sexual activity. This emphasizes the importance of safe sexual practices and raises awareness about the risks associated with gonorrhea transmission.
Health
JUST IN: JOHESU Launches Nationwide Strike Over Unresolved Demands
Members of the Joint Health Sector Unions and Assembly of Health Care Professionals (JOHESU) have announced a seven-day warning strike set to begin at midnight on Friday.
This action follows a 15-day notice of industrial action issued to the Federal Government.
READ MORE:Russia Battles Inflation, Raises Key Interest Rate To 21%
Addressing journalists in Abuja, JOHESU’s national chairman, Kabiru Minjibir, outlined the union’s primary demands, emphasizing a need for immediate action to address ongoing concerns affecting healthcare workers across the nation.
Key demands include the urgent implementation of the consolidated health salary structure and the payment of a 25 percent review of arrears from June to December 2023.
The union is also calling for an upward review of the retirement age for healthcare workers, a tax waiver on healthcare workers’ allowances, and the immediate disbursement of COVID-19 inducement hazard allowances.
Minjibir urged all union members nationwide to adhere to the strike directive, underscoring that compliance would be essential in pushing for their demands.
Details shortly………….
Health
Medical Emergency: Journalist, Kola Kuforiji Requires Financial Support
In a world where health is wealth, Kola Kuforiji, a Nigerian journalist who had worked for about two decades with Rhythm FM (Sliverbird Group) reporting business is facing an unthinkable challenge, and needs urgent help.
Kola, a 54-year-old husband and father of two, whose life was turned upside down when he was diagnosed with a drug-resistant, Parkinson’s disease with pronounced difficulty in walking and tremor has been very ill for more than two years and the severity and debilitating nature of his illness has depleted the finances of his family.
He was initially treated at Ikorodu General Hospital, Lagos, where a presumptive diagnosis of his medical condition was made.
ALSO READ: IPI Nigeria Secures Release Of OrderPaper Staff From DSS Custody
He was over a year ago referred to LASUTH, but there has been little improvement in his health.
Medical treatment abroad now offers the best option for his recovery with a recommendation from Atasehir Medicana International Hospital – Atasehir / Istanbul, Turkey confirming that he will need a Deep Brain Stimulation surgery.
The expected total cost of the Deep Brain Stimulation surgery with traveling expenses is put at $35,000 (USD) about N57 million at recent exchange rate.
Meanwhile friends of Kola have initiated moves to seek financial support from concerned citizens to help bridge the gap and ensure that he receives the care he needs to overcome this challenge.
A bank account to receive fund for the urgent medical intervention has been opened for donation that will bring hope and healing to Kola and his family.
Name of Account: SOS FOR JOURNALIST KOLA KUFORIJI
Account Number: 1790322317
Bank: Polaris Bank
Kola’s story is one of courage, resilience, and determination, but it’s also a story of urgent need.
He had worked for about two decades with Rhythm FM (Sliverbird Group) covering business at large and had contributed immensely to deepening understanding of the economy.
Over the years he has explored his media platform as a strong tool to drive financial inclusion and expanding frontier of knowledge of Nigerians on the activities and stride of the energy, banking and finance sectors at large to national development.
Despite his illness, Kola remains hopeful and determined to overcome.
Use this link to join SOS FOR JOURNALIST KOLA KUFORIJI WhatsApp group https://chat.whatsapp.
Health
Banning Tobacco Sales Could Save 1.2m Lives By 2095 – WHO
A new study from the World Health Organization (WHO) underscores the alarming connection between smoking and lung cancer, the leading cause of cancer-related deaths globally.
The research reveals that smoking accounts for approximately 85% of all lung cancer cases and warns that nearly three million lung cancer deaths could occur among those born between 2006 and 2010 if current trends persist.
Read Also: Emefiele’s Naira Redesign: Witness Uncovers Alleged Missteps, Political Influences
The findings, published in The Lancet Public Health, indicate that implementing a ban on tobacco sales for this generation—approximately 650 million individuals—could prevent about 1.2 million deaths by 2095.
This study is among the first to evaluate the potential impact of creating a tobacco-free generation and draws on data from 185 countries.
The research highlights significant disparities in preventable lung cancer deaths based on gender.
It found that over 45% of lung cancer deaths among men could be avoided, while nearly 31% could be prevented among women.
IARC researcher and co-author Isabelle Soerjomataram noted that the disparity is largely due to targeted marketing by the tobacco industry over the past decades.
Interestingly, the study also suggests that in regions like North America and parts of Europe, ending tobacco sales could lead to more preventable deaths among women than men.
In Western Europe, 78% of potential deaths among women could be averted, compared to nearly 75% among men in Central and Eastern Europe.
While the study offers a glimmer of hope, it cautions that not all lung cancer deaths can be prevented through tobacco sales bans alone.
Other risk factors, such as air pollution and second-hand smoke exposure, also significantly contribute to lung cancer rates.
Several countries have already implemented tobacco-free generation initiatives, including New Zealand, which became the first nation to ban cigarette sales to individuals born after 2008.
However, the new conservative government in New Zealand has announced plans to repeal this measure.
Conversely, the UK’s new Labour government is supportive of a similar initiative that restricts cigarette sales to anyone born after January 2009.
Despite the promising implications of tobacco-free generation policies, the authors of the IARC study stress that these measures must be part of a broader strategy to combat the health crisis posed by tobacco.
They advocate for additional approaches, such as increasing cigarette taxes, creating more smoke-free environments, and providing enhanced support for individuals looking to quit smoking.
As lung cancer remains a leading health challenge, this study highlights the urgent need for comprehensive tobacco control policies to protect future generations and reduce the burden of this deadly disease.